David Young

This profile gathers the share dealings of David Young in Processa Pharmaceuticals, Inc., where the filings describe the role as chief executive. We count 20 filings; the first trade dates from 23 June 2021 and the latest from 30 April 2026.

On the market, this insider has only ever bought: 10 purchases, €315k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 4 share grants and 5 option exercises. Since January 2026: 3 purchases and no sales on the market.

A typical purchase (the median) is worth €20k. Of 10 purchases, 7 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 1 May 2026, reports an open-market purchase of €3,913 in Processa Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.